ERBB2 and breast cancer: Lapatinib with chemotherapy and alternate combinatorial agents, including RTK inhibitors, endocrine therapy, CDK 4/6 inhibitors, or cholesterol pathway inhibitors, holds promise for HER2+ breast cancer patients.